THE IMPORTANCE OF MODELING INTEROCCASION VARIABILITY IN POPULATION PHARMACOKINETIC ANALYSES

被引:407
作者
KARLSSON, MO
SHEINER, LB
机构
[1] UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARM,SAN FRANCISCO,CA 94143
[2] UNIV CALIF SAN FRANCISCO,SCH MED,DEPT LAB MED,SAN FRANCISCO,CA 94143
[3] UPPSALA UNIV,FAC PHARM,DIV PHARMACOKINET,S-75123 UPPSALA,SWEDEN
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1993年 / 21卷 / 06期
关键词
INTEROCCASION VARIABILITY; INTERINDIVIDUAL VARIABILITY; INTRAINDIVIDUAL VARIABILITY; PHARMACOKINETICS; POPULATION ANALYSIS; NONMEM;
D O I
10.1007/BF01113502
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Individual pharmacokinetic parameters may change randomly between study occasions. Analysis of simulated data with NONMEM shows that ignoring such interoccasion variability (IOV) may result in biased population parameter estimates. Particular parameters affected and the extent to which they are biased depend on study design and tire magnitude of IOV and interindividual variability. Neglecting IOV also results in a high incidence of statistically significant spurious period effects. perhaps most important, ignoring IOV can lead to a falsely optimistic impression of the potential value of therapeutic drug monitoring. A model incorporating IOV was developed and its performance in the presence and absence of IOV was evaluated. The IOV model performs well with respect to both model selection and population parameter estimation in all circumstances studied. Analysis of two real data examples using this model reveals significant IOV in all parameters for both drugs and supports the simulation findings for the case that IOV is ignored: predictable biases occur in parameter estimates and previously nonexistent period effects are found.
引用
收藏
页码:735 / 750
页数:16
相关论文
共 12 条
[1]  
Beal SL., 2022, NONMEM 7 4 USERS GUI
[2]  
DAVIDIAN M, 1992, J PHARMACOKINETICS B, V20, P531
[3]  
GRAHNEN A, 1985, TOPICS PHARM SCI
[4]  
GRAVES DA, 1991, J PHARMACOKIN BIOPHA, V19, P485
[5]   APPLICATION OF THE NONMEM METHOD TO EVALUATION OF THE BIOAVAILABILITY OF DRUG PRODUCTS [J].
KANIWA, N ;
AOYAGI, N ;
OGATA, H ;
ISHII, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (12) :1116-1120
[6]   BIOAVAILABILITY ESTIMATION BY SEMISIMULTANEOUS DRUG ADMINISTRATION - A MONTE-CARLO SIMULATION STUDY [J].
KARLSSON, MO ;
BREDBERG, U .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1990, 18 (02) :103-120
[7]   A 3-STEP APPROACH COMBINING BAYESIAN REGRESSION AND NONMEM POPULATION ANALYSIS - APPLICATION TO MIDAZOLAM [J].
MAITRE, PO ;
BUHRER, M ;
THOMSON, D ;
STANSKI, DR .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (04) :377-384
[8]  
MALLET A, 1986, BIOMETRIKA, V73, P645
[9]   BUILDING POPULATION PHARMACOKINETIC PHARMACODYNAMIC MODELS .1. MODELS FOR COVARIATE EFFECTS [J].
MANDEMA, JW ;
VEROTTA, D ;
SHEINER, LB .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1992, 20 (05) :511-528
[10]  
ROWLAND M, 1980, BETTER SAFETY DRUGS